MediciNova Inc., a biopharmaceutical company listed on the NASDAQ and the Tokyo Stock Exchange, has provided an update on the enrollment status of two major clinical trials involving its developmental compounds MN-166 (ibudilast) and MN-001 (tipelukast). The ongoing Phase 2/3 COMBAT-ALS trial is nearing completion with only a single digit number of patients remaining to be randomized. In parallel, the Phase 2 trial targeting dyslipidemia and fatty liver disease in type 2 diabetes patients is seeking its final two participants. MediciNova anticipates top-line data from the ALS trial by the end of next year and is preparing for discussions with the FDA. Results for these trials have not yet been presented.